Which Side Effects Really Matter? Screening for Common and Distressing Side Effects of Antipsychotic Medications

2001 ◽  
Vol 7 (1) ◽  
pp. 41-47 ◽  
Author(s):  
PETER J. WEIDEN ◽  
ALEXANDER L. MILLER
Keyword(s):  
Side Effects ◽  
Antipsychotic Medications

scholarly journals Acute onset clozapine-induced hyperglycaemia: A case report

2019 ◽  
Vol 32 (2) ◽  
pp. e100045 ◽  
Author(s):  
Pradeep Kumar ◽  
Dheerendra Kumar Mishra ◽  
Nimisha Mishra ◽  
Sunil Ahuja ◽  
Gyanendra Raghuvanshi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Case Report ◽  
Side Effects ◽  
Atypical Antipsychotic ◽  
Time Frame ◽  
Acute Onset ◽  
Antipsychotic Medications ◽  
Pathophysiological Mechanisms ◽  
Hypoglycaemic Agent

Clozapine is an atypical antipsychotic which is described to have higher efficacy among all available antipsychotic medications. Clozapine is reserved especially for resistant schizophrenia due to its side effects. Clozapine-induced metabolic syndrome and hyperglycaemia are common long-term side effects and are responsible for increased mortality in patients with schizophrenia. In this case, a patient with resistant schizophrenia was presented with acute-onset hyperglycaemia and delirium with the use of clozapine within a week. Withdrawal of clozapine in the patient led to the improvement in delirium and hyperglycaemia without the use of any hypoglycaemic agent. This case supports the notion that in certain cases clozapine can induce hyperglycemia through possible direct pathophysiological mechanisms within a shorter time frame.

Applied monitoring for tardive dyskinesia and other extrapyramidal side effects

2012 ◽  
Vol 1 (7) ◽  
pp. 159-163 ◽  
Author(s):  
John E. Kalachnik
Keyword(s):  
Side Effects ◽  
Early Detection ◽  
Tardive Dyskinesia ◽  
Antipsychotic Drugs ◽  
Standard Of Care ◽  
Magic Bullet ◽  
Assessment Instruments ◽  
Extrapyramidal Side Effects ◽  
Antipsychotic Medications ◽  
Prevention Model

While the rate of tardive dyskinesia (TD) and other extrapyramidal side effects (EPSE) is lower with second generation antipsychotic medications compared to first generation antipsychotic medications, these side effects remain of clinical concern. This paper reviews the basis for the continued concern and the importance of secondary prevention, or early detection, within the primary-secondary-tertiary prevention model. The importance of standardized assessment instruments, education, and training is reviewed. Given the widespread use of antipsychotic drugs, the fact that antipsychotic drugs are the standard of care for several psychiatric conditions (with little indication that the magic bullet is on the immediate horizon to replace current antipsychotic drugs) applied monitoring and the early detection of TD and EPSE takes on added importance.

Psylog, an EPA smartphone application to prevent antipsychotic side-effects

2014 ◽  
Vol 29 (S3) ◽  
pp. 672-673
Author(s):  
O. Andlauer ◽  
M. Rojnic-Kuzman
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes ◽  
Side Effects ◽  
Psychiatric Care ◽  
Smartphone Application ◽  
Psychoeducational Intervention ◽  
Antipsychotic Medications ◽  
Antipsychotic Side Effects

Antipsychotic medications are used to treat a significant number of psychiatric disorders, such as schizophrenia or bipolar disorder, which have a significant impact on overall disability in Europe. Although these drugs have documented efficacy, they are also associated with side-effects such as drowsiness, weight gain, type 2 diabetes, or extrapyramidal symptoms [1]. These contribute to increasing overall morbidity and mortality [2], reduced quality of life, and can push patients to stop their medications. This often leads to relapse, and the need for a new hospital admission, which is detrimental to the patient, and create extra costs for the society. However, the monitoring of side-effects is rarely carried out in a standardized way in daily clinical practice. Smartphones are an acceptable and easy to use tool available to patients with schizophrenia [3]. The aim of the mPIVAS (mHealth psychoeducational intervention versus antipsychotic-induced side effects) project is to develop an effective and innovative smartphone application that can be used by psychiatrists and patients in order to monitor medications’ side-effects. The European Psychiatric Association (EPA) is involved in this project with the objective to develop this application in 6 languages. Part of the project includes training European early careers psychiatrists to the use Psylog and helping them to spread information about this new project in their own country, by organising local and national cascade courses. We expect an improvement in psychiatric care in all involved institutions through the education of employees, a better implication of patients in their disease, and an improved monitoring of antipsychotic side-effects.

scholarly journals Metabolic Side Effects of Antipsychotic Medications: Clinical Laboratory Implications

2004 ◽  
Vol 35 (10) ◽  
pp. 625-627
Author(s):  
Thomas E. Hansen ◽  
Kristen Snyder ◽  
Erik Messamore ◽  
William F. Hoffman
Keyword(s):  
Side Effects ◽  
Clinical Laboratory ◽  
Antipsychotic Medications ◽  
Metabolic Side Effects

scholarly journals Minimal – no, minimise – yes

2009 ◽  
Vol 15 (3) ◽  
pp. 218-220 ◽  
Author(s):  
Larkin Feeney
Keyword(s):  
Side Effects ◽  
Strong Evidence ◽  
Mental Healthcare ◽  
Antipsychotic Medications

SummaryThis commentary questions evidence put forward in support of minimal-medication approaches to the treatment of schizophrenia. Psychiatrists should indeed seek to minimise the amount of medication that they use in order to reduce the incidence of side-effects. However, there is strong evidence that antipsychotic medications do help people with psychosis towards recovery. In practice, psychiatrists do not rigidly follow guidelines recommending medication, but rather work with and support individuals in a broad-based way to make informed choices about their mental healthcare.

scholarly journals A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications

2016 ◽  
Vol 53 (2) ◽  
pp. 163-175 ◽  
Author(s):  
Julie Kreyenbuhl ◽  
Lisa B. Dixon ◽  
Clayton H. Brown ◽  
Deborah R. Medoff ◽  
Elizabeth A. Klingaman ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Side Effects ◽  
Controlled Trial ◽  
Patient Centered ◽  
Antipsychotic Medications ◽  
Randomized Controlled ◽  
Metabolic Side Effects

Sexual side effects of novel antipsychotic medications

2002 ◽  
Vol 56 (1-2) ◽  
pp. 25-30 ◽  
Author(s):  
Donna A Wirshing ◽  
Joseph M Pierre ◽  
Stephen R Marder ◽  
C.Scott Saunders ◽  
William C Wirshing
Keyword(s):  
Side Effects ◽  
Antipsychotic Medications ◽  
Sexual Side Effects ◽  
Novel Antipsychotic

scholarly journals Attitude towards Antipsychotic Medications in Patients Diagnosed with Schizophrenia: A Cross-Sectional Study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Tilahun Kassew ◽  
Demeke Demilew ◽  
Addis Birhanu ◽  
Mesele Wonde ◽  
Biks Liyew ◽  
...  
Keyword(s):  
Side Effects ◽  
Linear Regression ◽  
Associated Factors ◽  
First Generation ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Antipsychotic Medications ◽  
Specialized Hospital ◽  
The Mean

Background. Poor attitude towards antipsychotic drugs is high, and it is a factor for non-adherence to treatment. This increases the risk of relapse, associated healthcare utilization, and costs. This study aimed to assess attitude towards antipsychotic medication among patients with schizophrenia. Objectives. The aim of this institution based cross-sectional study was to assess attitude towards antipsychotic medications and associated factors among patients with schizophrenia who attend the outpatient clinics at Amanuel Mental Specialized Hospital, 2018. Methods. In a cross-sectional study, 393 schizophrenic patients from Amanuel Mental Specialized Hospital were recruited by a systematic random sampling technique. Drug Attitude Inventory (DAI-10) was used to assess attitude, experience, and belief about antipsychotics. Glasgow antipsychotic side effect scale modified version, positive and negative syndrome scale, and Birch wood’s insight scale for psychosis were the instruments used to assess the associated factors. Simple and multiple linear regression analysis models were fitted, and the adjusted unstandardized beta (β) coefficient at 95% confidence interval was used. Results. The mean score of attitude towards antipsychotic medications was 6.51 with standard deviation (SD) of 2.22. In multiple linear regression, positive symptoms (β= -0.07, 95% CI: (-0.09, -0.05)), negative symptoms (β= -0.04, 95% CI: (-0.06,-0.02)), shorter (≤5 years) duration of illness (β= -0.39, 95% CI: (-0.63, -0.15)), first generation antipsychotics (β = -0.35, 95% CI: (-0.55,-0.14)), having sedation (β= -0.28, 95% CI: (-0.52, -0.02)), and extra-pyramidal side effects (β= -0.34, 95% CI: (-0.59,-0.09)) were factors negatively associated with attitude towards antipsychotic medication treatment. Insight to illness (β= 0.24, 95% CI: (0.20, 0.27) was a factor positively associated with attitude towards antipsychotic medications. Conclusion. The result suggests that the mean score of participants’ attitude towards antipsychotic medications was good. Prevention of side effects particularly due to first generation antipsychotics is necessary.

Sign in / Sign up

Export Citation Format

Share Document